Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 60

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 60
---
2025, we closed
our reasonable best efforts public offering, with participation from a member of our board of directors and a single institutional investor,
for the purchase and sale of (i) 2,551,020 shares of Common Stock or common stock equivalents in lieu thereof; and (ii) February 2025
Common Warrants to purchase up to 2,551,020 shares of common stock, at a combined public offering price of $1.96 per share and warrant.
In connection with the offering, on February 5, 2025, we entered into the SPA with the investors. Such transaction is referred to as the
“February 2025 Offering.” The shares of Common Stock and the Warrants described above and the shares of Common Stock underlying
the Warrants were offered pursuant to the Registration Statement on Form S-1 (File No. 333-284007), as amended, which was declared effective
by the Securities and Exchange Commission on February 5, 2025. In connection with this offering, we received net proceeds of approximately
$4.3 million.

31

April 2025 PIPE Financing

On April 21, 2025, the Company
consummated a private placement of 6,250 shares of Series D Preferred Stock pursuant to the Securities Purchase Agreement, for aggregate
proceeds of approximately $5 million, paid through the transfer of certain Transfer Shares (as defined in the Securities
Purchase Agreement) in lieu of cash, and agreed to issue up to 3,750 additional shares of Series D Preferred Stock for cash proceeds of
up to $3 million at one or more additional closings. Each additional closing is at the option of the investors upon notice to the Company
and subject to satisfaction of customary closing conditions.

On April 22, 2025, the Company
filed the Certificate of Designations of Rights and Preferences of the Series D Preferred Stock (the “Certificate of Designations”)
for the purpose of designating and establishing the Company’s Series D Preferred Stock. The Certificate of Designations was filed
pursuant to the Securities Purchase Agreement, dated April 21, 2025, with certain accredited investors named therein. The Certificate
of Designations became effective on April 22, 2025.

Investigational New Drug
Application Submission

On June 28, 2024, the Company
submitted an Investigational New Drug Application (“IND”) for its product candidate, CER-1236,